<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809236</url>
  </required_header>
  <id_info>
    <org_study_id>KHSWKH902008</org_study_id>
    <nct_id>NCT01809236</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion</brief_title>
  <acronym>FALCON</acronym>
  <official_title>An Open Label, Single Arm Clinical Study of Intravitreal Injection of Conbercept in Patients With Maculae Edema Secondary to Retinal Vein Occlusion (the FALCON Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu Kanghong Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chengdu Kanghong Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30 BRVO&#xD;
      and 30 CRVO, respectively) are enrolled in the study. The study included a fixed treatment&#xD;
      period (3 months) and a PRN period (6 months). In the fixed treatment period patients will&#xD;
      receive 3 consecutive monthly intravitreal of 0.5 mg Conbercept. In the PRN period, patients&#xD;
      are monthly visited and retreatment will be needed according to the retreatment criteria&#xD;
      pre-specified.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in BCVA</measure>
    <time_frame>3-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in BCVA</measure>
    <time_frame>baseline to 9-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in central retinal thickness</measure>
    <time_frame>baseline to 9-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean injection times</measure>
    <time_frame>baseline to 9-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Macular edema volume and other anatomical character in the study eye</measure>
    <time_frame>baseline to 9-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse event</measure>
    <time_frame>3-month and 9-month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>0.5 mg Conbercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive monthly intravitreal injections of Conbercept to month 3 (total 3 times) and then on an as needed (PRN) dosing schedule based on the pre-specified retreatment criteria till to month 9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conbercept</intervention_name>
    <description>intravitreal injection of 0.5 mg Conbercept</description>
    <arm_group_label>0.5 mg Conbercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability and willingness to provide signed Informed Consent Form.&#xD;
&#xD;
          2. Age ≥ 18, both male and female。&#xD;
&#xD;
          3. Ocular Inclusion Criterion (Study Eye):&#xD;
&#xD;
               -  Diagnosis of Foveal center-involved macular edema due to RVO (both CRVO and BRVO)&#xD;
                  within 6 months.&#xD;
&#xD;
               -  Best corrected visual acuity (BCVA) letter score in the study eye of ≤ 73（Snellen&#xD;
                  equivalents 20/40）.&#xD;
&#xD;
               -  Central retinal thickness by OCT in the study eye ≥ 320 μm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Brisk afferent pupillary defect.&#xD;
&#xD;
          2. History of any anti-VEGF treatment in the study and/or system within 6 months before&#xD;
             enrollment, and/or in the fellow eye within 3 month.&#xD;
&#xD;
          3. History of intraocular and/or peri-ocular corticosteroid use in the study eye within 3&#xD;
             months, and/or history of use steroids systemic (p.o., i.m., i.v.) within 1 month.&#xD;
&#xD;
          4. Any active infection involving the ocular including blepharitis, infectious&#xD;
             conjunctivitis, keratitis, scleritis, endophthalmitis in either eye.&#xD;
&#xD;
          5. Any inflammatory cells detected in the anterior chamber and/or vitreous in the study&#xD;
             eye.&#xD;
&#xD;
          6. Presence of non-RVO disease, in the opinion of the investigator, might cause macular&#xD;
             edema, such as AMD (wet or dry), diabetes retinopathy, uveitis etc.&#xD;
&#xD;
          7. Neovascular change in the study eye and/or neovascularization of the iris or&#xD;
             neovascular glaucoma in study eye at baseline.&#xD;
&#xD;
          8. Patients with substantial cataract that, in the opinion of the investigator, is likely&#xD;
             to be decreasing visual acuity by equal or more than 3 lines or medicine or surgery&#xD;
             treatment are needed in the study eye within 4 months.&#xD;
&#xD;
          9. Patients diagnosed with systemic immune diseases and any uncontrolled clinical&#xD;
             disease.&#xD;
&#xD;
         10. Pregnant or nursing women.&#xD;
&#xD;
         11. Patients need to exclude in the opinion of investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Tongren hospital affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Eye Hospital of WMC</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 11, 2013</study_first_submitted>
  <study_first_submitted_qc>March 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2013</study_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

